Marc Remke

This study identifies CCR2 as a biomarker and therapeutic target in Group 3 medulloblastoma, showing its association with dissemination and poor survival, and demonstrating therapeutic efficacy through Cenicriviroc.

This study evaluates the impact of R-CHOP chemotherapy on NK cell viability and function in DLBCL cell lines and patients, finding that treatment reduces NK cell numbers but preserves their cytotoxicity.

This study identifies GALE as a key regulator of glycoproteome remodelling in RAS-driven cancer, showing its role in sialylation and tumorigenicity.

This study examines hTERT expression and its prognostic impact in pediatric medulloblastoma, finding higher expression correlates with worse survival outcomes.

This study shows that EIF4EBP1 is upregulated by MYC in medulloblastoma and linked to poorer patient survival.

This study identifies H1-0 as a mediator of ETV6::RUNX1-induced quiescence in BCP-ALL preleukemic cells and suggests HDACi treatment as a potential therapeutic approach.

This study shows oncogenic RAS signaling suppresses ferroptosis by upregulating GCH1 and BH4, making RAS-driven cancers resistant to ferroptosis-inducing agents.

This study integrates phospho-proteogenomic and single-cell transcriptomic data to subtype meningiomas and identify subtype-specific immune infiltration patterns.